Sushi repeat-containing protein X-linked 2 (SRPX2) is a novel protein associated with language development, synaptic plasticity, tissue remodeling, and angiogenesis. We investigated the expression and spatial localization of SRPX2 in normal mouse, rat, monkey, and human brain using in situ hybridization and immunohistochemistry. Antibody specificity was determined using in vitro siRNA based silencing of SRPX2. Cell type-specific expression was verified by double-labeling with oxytocin or vasopressin. Western blot was used to detect SRPX2 protein in rat and human plasma and cerebrospinal fluid. Unexpectedly, SRPX2 mRNA expression levels were strikingly higher in the hypothalamus as compared to the cortex. All SRPX2 immunoreactive (ir) neurons were localized in the hypothalamic paraventricular, periventricular, and supraoptic nuclei in mouse, rat, monkey, and human brain. SRPX2 colocalized with vasopressin or oxytocin in paraventricular and supraoptic neurons. Hypothalamic SRPX2-ir positive neurons gave origin to dense projections traveling ventrally and caudally toward the hypophysis. Intense axonal varicosities and terminal arborizations were identified in the rat and human neurohypophysis. SRPX2-ir cells were also found in the adenohypophysis. Light SRPX2-ir projections were observed in the dorsal and ventral raphe, locus coeruleus, and the nucleus of the solitary tract in mouse, rat and monkey. SRPX2 protein was also detected in plasma and CSF. Our data revealed intense phylogenetically conserved expression of SRPX2 protein in distinct hypothalamic nuclei and the hypophysis, suggesting its active role in the hypothalamo-pituitary axis. The presence of SRPX2 protein in the plasma and CSF suggests that some of its functions depend on secretion into body fluids.
cortex and SRPX2 silencing impairs ultrasonic vocalizations in mice (Roll et al., 2006; Sia, Clem, & Huganir, 2013) . SRPX2 interacts with the urokinase-type plasminogen activator receptor (uPAR) and the SRPX2-uPAR interaction initiates neuronal migration in the cerebral cortex and increases spine density in distal dendrites, resulting in increased cortical excitability (Salmi et al., 2013) . The SRPX2-uPAR interaction is regulated by the transcription factor FOXP2, mutations of which cause severe speech and language disorders (MacDermot et al., 2005; RoyerZemmour et al., 2008) .
Studies of glioblastoma (Tang et al., 2016a) , gastric cancer (Tanaka et al., 2009) , liver cancer (Lin, Chang, Wang, Tian, & Yu, 2017) , and colorectal cancer (Liu, Wu, Zhou, & Fan, 2015; Øster et al., 2013) showed that SRPX2 is a secreted protein whose expression increases angiogenesis and adhesion of cancer cells. An increased level of tissue SRPX2 is a predictive biomarker for a poor outcome in patients with hepatocellular carcinoma (Lin et al., 2017) . The function of SRPX2 in cancer cells requires interaction with uPAR on the cell surface and engagement of membrane co-receptors, such as a v b3 integrin and PDGFRb receptors. This results in intracellular activation of the P12k/ Akt, Ras/MAPK, and P-FAK/Akt pathways, eventually activating MMP2 and MMP9 matrix metalloproteinases (Lin et al., 2017; Liu, Fan, & Wu, 2017; Tang et al., 2016b; Yamada et al., 2014) . Expression of SRPX2 in colorectal cancer is regulated by nonCpG island promoter hypomethylation and post-transcriptionally by miR-149 (Øster et al., 2013 ).
The well-defined effects of SRPX2 on language learning, angiogenesis, and synaptic plasticity make SRPX2 a promising target to modulate tissue repair after brain injury or disease. Surprisingly, there are no descriptions of the cellular localization of SRPX2 in the cortical and subcortical areas of the brain, and of possible species differences.
Therefore, we investigated the spatial distribution of SRPX2 protein in normal mouse, rat, monkey, and human brain, and profiled the neurons expressing SRPX2 protein. As we observed SRPX2 in hypothalamopituitary projections, we also determined its presence in the plasma and cerebrospinal fluid (CSF).
| M A TE RI A L S A ND M E TH ODS
2.1 | Specificity of SRPX2 antibody
| Cell line selection
We first confirmed the specificity of rabbit anti-SRPX2 antibody (ab91584, Abcam), which was used in most of the immunostainings, by in vitro siRNA based silencing of SRPX2 protein in cell cultures. In order to select a suitable cell line, we screened one primary and six secondary cell cultures for endogenous expression of SRPX2 using RT-qPCR and Western blot. Among these, mouse P19 embryonal carcinoma derived cells, mouse N2a neuroblastoma cell line, human n2012 teratocarcinomas cells, primary mouse E18 cortical cells, differentiated iPSCs cells, and human SH-SY5Y neuroblastoma cells all endogenously expressed SRPX2 mRNA. SH-SY5Y cells with abundant expression of SRPX2 mRNA and protein were selected for transfection with SRPX2 siRNA and subsequent antibody validation.
SH-SY5Y were cultured and maintained in DMEM/ F12 1 GlutaMAX (Dulbecco's Modified Eagle Medium/Nutrient Mixture F-12, Gibco, Gaithersburg, MD) with PenStrep (penicillin-streptomycin, 100 units/ml) as antibiotics. All cells were maintained at 378C in a 5% CO 2 atmosphere. Cells were plated into 12-well plates (150,000 cells/well) for siRNA transfection and allowed to adhere overnight.
| siRNA transfection
Pre-designed Silencer® siRNA against human SRPX2 mRNA was used (AM16708, Ambion) for transfection of SH-SY5Y cells using Lipofectamine® 2000 (Thermo Fisher Scientific). Silencer® FAM-labeled negative control siRNA (AM4620, Ambion) was transfected parallel to SRPX2 siRNA to ensure transfection efficiency and specificity. Transfection was carried out according to manufacturer's protocol. Briefly, cells were treated with SRPX2 siRNA (10-50 nM) or negative control siRNA (10-50 nM) for 48 hr. Untreated cells were processed at the same time for comparison and all the transfections were carried out in triplicate. After 48 hr, the cells were washed with PBS and frozen at 2708C overnight. Transfection outcome was evaluated using a systematic approach. First, RNA from mock-transfected and SRPX2 siRNA transfected cells was assayed for SRPX2 mRNA quantification by RTqPCR, and the transfection conditions were optimized until a more than twofold reduction in the transcript was achieved. Then, the optimized transfection was evaluated for antibody specificity using Western blotting and immunofluorescence staining.
| Real-time quantitative PCR
RT-qPCR analysis was carried out to test the reduction in SRPX2 mRNA after transfection. Total RNA was harvested using AllPrep DNA/RNA Mini Kit (QIAGEN®, Hilden, Germany), quantified by NanoDrop TM (ND-1000) and evaluated for quality by checking the RNA Integrity Number (RIN) (Agilent Bioanalyzer). Samples with RIN 9 and above were included in the analysis. cDNA from 0.5 lg of total RNA was synthesized using high-capacity RNA-to-cDNA Kit (Applied Biosystems, Foster City, CA) and amplified using TaqMan® Gene Expression
Master mix (Applied Biosystems). The human SRPX2 TaqMan® gene expression assay (Hs00997580, Thermo Fisher Scientific) was used for SRPX2 mRNA amplification. As a stable endogenous control, b-actin was measured simultaneously (Armstrong et al., 2007) using the human ACTB TaqMan® assay (Hs03023943-g1, Thermo Fisher Scientific).
The program for RT-qPCR reaction was as follows: one cycle (508C-120 s), one cycle (958C-600 s) and 50 cycles (958C 215 s, 608C-60 s).
All assays were performed according to the manufacturer's protocol.
SRPX2 mRNA level values were normalized to ACTB mRNA levels and expressed as fold-increase relative to gene expression in untreated control cells. The relative expression level (fold change) of the target gene was calculated using the 2 2DDCT method and the knockdown percentage (%KD) was calculated using the equation, %KD 5
(1 2 DDC T )*100, where, DDC T is the normalized expression of the target (Schmittgen & Livak, 2008 For in situ hybridization, rat brains were fixed in 10% buffered formalin and embedded in paraffin. Sagittal sections (6 mm) were cut using a microtome, collected on glass slides, and stored at RT until use.
| Monkey
Hypothalamic and brainstem sections from two female adult Macaca arctoides monkeys (weight 7-8 kg) were used for SRPX2 immunohistochemistry. The maintenance of the monkeys and all procedures of the study were carried out according to the Finnish law and statutes governing animal experimentation. The Finnish Ministry of Agriculture had approved of the studies performed on monkeys.
The monkeys were deeply anesthetized with a cocktail of Ketalar (1 ml) and Nembutal (4.5 ml). The animals were perfused intracardially with 0.9% saline (250 ml/min) for 2 min at RT followed by a solution of 4% PFA and 0.1% glutaraldehyde in 0.1 M sodium phosphate buffer for 10 min at the rate of 250 ml/min and then 50 min at the rate of 100 ml/min. The brain was removed from the skull and post-fixed for 2 hr at 48C in the above fixative. The brain tissue was then cryoprotected in 10% glycerol and 2% dimethylsulfoxide (DMSO) solution for 24 hr, in 20% glycerol and 2% DMSO solution for 3 days at 48C, and then frozen by immersion in ice cold isopentane (2-methyl butane). Coronal sections of the brain (30 mm) were cut in a 1-in-8 series and stored in TCS at 2708C until stained.
| Human
Autopsy ( For in situ hybridization, 6-mm-thick coronal sections were cut from paraffin embedded human tissue and collected on glass slides.
The slides were dried and stored at RT until use.
| Nissl staining
To identify the cytoarchitectonic boundaries of different brain areas to optimize the selection of sections for analyses, the first series of sections was used for Nissl staining (Huusko, R€ omer, Ndode-Ekane, Lukasiuk, & Pitkänen, 2015) . The sections were mounted on glass slides coated with 0.5% gelatin (G-2500, MilliporeSigma, Burlington, MA), rehydrated in decreasing grades of alcohol, stained for thionin, dehydrated in increasing grades of alcohol and cover-slipped with mounting medium (Depex® BDH Chemical, Poole, UK).
| In situ hybridization
In situ hybridization for SRPX2 mRNA was performed on rat and human hypothalamic sections using 5
RNA moieties (Exiqon, Vedbaek, Denmark). To detect both rat (NM_001108243.2) and human (NM_014467.2) SRPX2 mRNA, the probe was designed using a conserved sequence 5 0 DIG-
where "L" indicates LNA and "m" indicates [2 0 OMe] RNA moieties (Exiqon). Briefly, the sections were deparaffinized in xylene and graded ethanol (100% and 70%) for 3 min each. Endogenous peroxidase activity was blocked by incubating the sections in 0.3% H 2 O 2 in methanol for 20 min. After washing with sterile water, the sections were immersed in Na-citrate buffer (pH 6) and heated at 958C for 10 min to improve tissue permeability. The sections were then hybridized with the SRPX2 mRNA probe (250 nM) in the hybridization mix (50% deionized formamide, 600 mM NaCl, 10 mM HEPES buffer, pH 7.5, 1 mM EDTA, 5X Denhardt's reagent) at 568C for 1 hr. After hybridization, the tissue sections were washed with 2X SSC (saline sodium citrate, pH 5), 0.5X SSC and 0.2X SSC buffers for 2 min each at 568C. The sections were blocked for 15 min with phosphate buffered saline (PBS) containing 1% bovine serum albumin, 0.02% Tween 20, and 1:100 normal goat serum (NGS). Sheep anti-DIG alkaline phosphatase (AP) (1:1,500, 1093274, Roche) prepared in blocking buffer was added to the sections for 1 hr at RT. NBT (nitro-blue tetrazolium chloride)/BCIP (5-bromo-4-chloro-30-indolyphosphate p-toluidine salt) was used as chromogenic substrate for AP to detect the SRPX2 mRNA hybridization.
The slides were mounted with VectaMount at RT.
For double-labeling, in situ hybridization was followed-up by immunohistochemistry. Briefly, after developing the chromogenic reaction for SRPX2 mRNA, the slides were washed with PBS, blocked with PBS containing NGS, and incubated with anti-SRPX2 antibody for 1 hr overnight at 378C. The staining reaction was intensified using 0.005% osmium tetroxide (OsO4, #19170, Electron Microscopy Sciences, Hatfield, PA) as previously described (Lewis, Campbell, & Morrison, 1986) .
Slides were covered with Depex ® and dried overnight in the hood.
| Monkey and human
The protocol for immunohistochemistry was the same as used for rodent tissue, except that the sections were pre-treated with 1% sodiumborohydride for 15 min before blocking. In human, sections containing hypothalamus were stained. In monkeys, sections including the brainstem were also stained. (West, Slomianka, & Gundersen, 1991) . Data is expressed as mean 6 SEM.
| Immunofluorescence double-labeling
To identify the cell types expressing SRPX2, rat hypothalamic sections were double-labeled with either oxytocin or vasopressin antibodies. 
| Human plasma
Blood samples were obtained from the cubital vein of healthy adult male and female subjects (n 5 3) at Kuopio University Hospital between 7:00 a.m. and 8:00 a.m. The samples were centrifuged (2,2003g for 10 min at RT), plasma was collected and stored at 2708C.
| Human CSF
CSF samples (n 5 3) were obtained through lumbar puncture performed at Kuopio University Hospital between 9:00 a.m. and 11:00 a.m. After brief mixing, the samples were centrifuged (2,0003g for 10 min at RT), supernatant was collected and stored at 2708C.
| Western blot
Total protein concentration in plasma and CSF was measured using 
| R E SU LTS

| Specificity of SRPX2 antibody
As there are no prior reports on the immunohistochemical location of SRPX2 in hypothalamic neurons, we first confirmed the specificity of the antibody using small interfering RNA (siRNA) to silence the SRPX2 mRNA in vitro. We screened cell lines for endogenous SRPX2 expression and selected the human SH-SY5Y neuroblastoma cells for siRNA transfection (Figure 1a-c) . After transfection, we analyzed SRPX2 mRNA expression using RT-qPCR ( Figure 1d ) and SRPX2 protein antibody, confirmed a marked reduction in SRPX2 protein as compared with untreated and mock-transfected cells (Figure 1f-h ).
The transfection efficiency was evaluated under a microscope by FAM-labeled negative control siRNA, which was localized inside the cell after 24 hr of transfection (Figure 1i ). The cell viability assay
showed an approximately 17% decrease in cell numbers of the transfected wells when compared to untreated cells and normalized with the absorbance of the dead cell control and media only. This change was comparable in all transfections and not due to anti-SRPX2 siRNA transfection ( Figure 1j ). All of the above findings confirmed the specificity of the SRPX2 antibody used in this study.
| SRPX2 expression in normal brain
In order to identify the precise location of SRPX2 mRNA in normal brain, we labeled sections from rat ( Figure 2a ) and human brain ( Figure   2b ) using in situ hybridization. High levels of SRPX2 expression were detected in the hypothalamic paraventricular (Pa), periventricular (Pe) and supraoptic (SO) nuclei. We then stained brain sections for SRPX2 protein using immunohistochemistry (Figure 2c,d ) with a SRPX2 antibody (polyclonal rabbit anti-SRPX2, ab91584, Abcam). The staining showed immunoreactivity in the same regions of the rat (Figure 2c ) and (Figure 2g ).
3.3 | SRPX2 is expressed in hypothalamic neurons and its distribution is highly conserved between rodents and primates
| Rat
In rat brain, all SRPX2-ir neurons were located in the hypothalamus (Figure 3a) , particularly in the Pa, Pe (Figure 3a 1 ), and SO nuclei ( Figure   3a 2 ). In the Pa, SRPX2-ir neurons were distributed bilaterally in all functional compartments within the nucleus, including the neurosecretory magnocellular neurons, endocrine, and pre-autonomic parvocellular neurons (Ferguson, Latchford, & Samson, 2008; Loewen et al., 2017; Swanson & Sawchenko, 1983) . The cytoplasmic SRPX2 protein had a granular appearance when observed at a higher magnification ( Figure   3c ). In the Pe, SRPX2-ir cells were scattered along its complete rostro-caudal axis. The SO nucleus exhibited strong SRPX2 immunoreactivity. A few scattered SRPX2-ir neurons were also observed in the supraoptic decussation part and the nucleus circularis. Stereological cell counting revealed 2495 6 215 SRPX2 neurons in the Pa (32% of all SRPX2-ir neurons in the hypothalamus), 835 6 94 in the Pe (11% of all ir neurons), and 4520 6 292 in the SO nucleus (58% of all ir neurons).
Hypothalamic SRPX2-ir neurons gave origin to a dense projection that traveled ventrally and caudally toward the hypophysis (Figure 3b ). 
| Mouse
Like in rat, also in the mouse brain SRPX2-positive neurons were exclusively located in the hypothalamus (Figure 3d ). In the mouse hypothalamus, the estimated total number of SRPX2-ir neurons was 1843 6 303 in the Pa (58% of all ir neurons), 503 6 85 in the Pe (16% of all SRPX2-ir neurons in the hypothalamus), and 837 6 108 in the SO nuclei (26% of all ir neurons).
Also like in rat, we detected no immunoreactivity in the cortex.
| Monkey and human
Analysis of monkey and human hypothalamic sections indicated that the spatial distribution of hypothalamic SRPX2-ir neurons was consistent among rodents and primates (Figure 3e,f) .
| SRPX2 colocalizes with oxytocin or vasopressin in the hypothalamus
The Pa and SO nuclei synthesize oxytocin and vasopressin, which are then transported to the hypophysis, and secreted into the blood stream (Swanson & Sawchenko, 1983) . As the light-microscopic location of SRPX2 in the Pa and SO suggested colocalization, we next performed double-labeling of SRPX2 with oxytocin or vasopressin in the rat hypothalamus. Approximately 88% of SRPX2-ir neurons in the Pa and 61%
in the SO were also immunoreactive for oxytocin (Figure 5a-c) .
Double-immunofluorescence also indicated colocalization of SRPX2 with vasopressin (Figure 5d-f ).
| SRPX2 in the hypophysis
We observed heavy axonal projections from the rat hypothalamic SRPX2-ir neurons to the hypophysis. In the rat posterior pituitary, we found dense terminal arborizations (Figure 5g,h ). In the human neurohypophysis, SRPX2 immunoreactivity was observed in the terminals and axonal Herring bodies (Figure 5j,k) . The cells in the rat (Figure 5i) and human ( Figure 5l ) adenohypophysis exhibited cytoplasmic vesiclelike SRPX2 immunoreactivity.
| SRPX2 protein in plasma
After determining the distribution of SRPX2 in the brain, we investigated whether SRPX2 protein is secreted to rat and human blood, and CSF. Using Western blot, we detected a 53 kDa SRPX2 immunoreactive band in rat and human plasma with two different SRPX2 antibodies. SRPX2 protein was also detected in human CSF from the same cases ( Figure 5m ). SRPX2 protein was detected in both male and female human plasma and CSF samples.
| D I SCUSSION
We report a phylogenetically conserved neuronal expression of SRPX2 protein in the Pa, Pe, and SO nuclei of the mouse, rat, monkey, and human hypothalamus, and SRPX2-ir projections to the neurohypophysis and brainstem ( Figure 6 ). We also demonstrated the colocalization of SRPX2 protein with oxytocin or vasopressin, and show SRPX2 protein in rat and human plasma, and human CSF. In addition, we validate the specificity of anti-SRPX2 antibody according to the recommendations of International Working Group for Antibody Validation (Uhlen et al., 2016) .
SRPX2 has been identified as a language-associated protein and in utero silencing of SRPX2 impairs ultrasonic vocalizations in mouse pups (Sia et al., 2013) . This is consistent with human studies suggesting an association of SRPX2 and FOXP2 gene mutations with language impairment (Roll et al., 2006 (Roll et al., , 2010 Sia et al., 2013) . Surprisingly, we found that SRPX2 protein was expressed in the hypothalamic nuclei instead of the ultrasonic vocalization related temporal cortex in mice and rats. We employed multiple staining strategies to verify the staining pattern. Fresh frozen, fixed frozen, and paraffin embedded tissue was used for immunohistochemistry using two different antibodies.
We also used 10 mM sodium citrate buffer (pH 6 at 958C) in rat tissue, and sodium borohydride in monkey and human brain tissue. However, none of these approaches showed distinct SRPX2 immunoreactivity in the cortex. Hypothalamic staining was consistently detected in all types of staining strategies.
The SRPX2 protein colocalized with oxytocin or vasopressin in the Pa and SO nuclei. This suggests a role of SRPX2 in neuroendocrine functions. Interestingly, oxytocin-expressing neurons in the Pa have an important role in social communication, including vocal learning and language (Pfundmair, Lamprecht, von Wedemeyer, & Frey, 2016; Theofanopoulou, Boeckx, & Jarvis, 2017; Ye, Stolk, Toni, & Hagoort, 2016; Zhang et al., 2016) . Similar to SRPX2, oxytocin knockout mice exhibit reduced ultrasonic vocalizations (Theofanopoulou et al., 2017; Winslow et al., 2000) . These data together with our findings suggest that SRPX2 protein expression in the hypothalamus, like in the language cortex, may also play a role in ultrasonic or verbal communication.
Most of the SRPX2-ir neurons were located in the Pa, which has three functional compartments. These include the neurosecretory magnocellular neurons projecting to the posterior pituitary, the neuroendocrine parvocellular neurons projecting to the median eminence, and the pre-autonomic parvocellular neurons projecting to the nucleus tractus solitarius, rostral ventrolateral medulla, and spinal cord (Ferguson et al., 2008; Loewen et al., 2017; Swanson & Sawchenko, 1983) . This explains the observed topographic organization of SRPX2-ir projections to the hypophysis and brainstem.
The hypothalamus-pituitary axis regulates the fundamental endocrine and autonomic functions necessary for survival in both rodents and humans. Hypothalamic injury may lead to chronic pituitary dysfunction (Tanriverdi et al., 2015) . For instance, vasopressin-expressing neurons regulate the water balance in the body, and their dysregulation due to traumatic brain injury (TBI) causes diabetes insipidus (Capatina, Paluzzi, Mitchell, & Karavitaki, 2015) . Taken together, in addition to language development, SRPX2 protein mediated mechanisms can present a novel target to modulate neuroendocrine and autonomic functions of the hypothalamo-pituitary and hypothalamo-brainstem axis in normal and diseased brain. 
